Sanofi

Aventis Pharma S.a.

Victor Certal

Frank Halley

Fabienne Thompson

Laurent Schio

Youssef El-Ahmad

Maurice Brollo

Michel Tabart

Gary Mccort

Bruno Filoche-Romme

Corinne Terrier

Karl Andreas Karlsson

Monsif Bouaboula

Jean-Christophe Carry

Hartmut Strobel

Kurt Ritter

Jean-Marie Ruxer

Patrick Mailliet

Sven Ruf

Franck Slowinski

Gilles Doerflinger

Eric Didier

Maria Mendez-Perez

Eric Nicolai

Hervé Minoux

Youssef El Ahmad

Patrick Mougenot

Marcel Alasia

Luc Bertin

Corinne Venot

Bruno Filoche-Rommé

Frédéric Petit

Anne-Marie Periers

Anne Dagallier

Marc Bianciotto

Patrick Bernardelli

Alice Da Rocha

Béatrice De Bruin

Youssef El-ahmad

Bruno Filoche-RommÉ

Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof

The present disclosure relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (I-A), wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SERM-F represents a selective estrogen receptor modulator fragment comprising an aryl or heteroaryl group linked to the adjacent 'A' group. The disclosure also relates to the preparation and to the therapeutic uses of the compounds of formula (I-A) as inhibitors and degraders of estrogen receptors. 

Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a &#x2014;COOH, a &#x2014;OH or a &#x2014;OPO(OH)group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a &#x2014;OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a &#x2014;COOH, &#x2014;OH or &#x2014;OPO(OH)group, then R5 represents a hydrogen atom; when R5 represents a &#x2014;OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group;and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors.

Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

The invention relates to the novel materials of formula (I), wherein each of the substituents R, R1, R2, R3, R4 and R5 is as defined herein. The materials are useful as inhibitors of AKT(PKB) phosphorylation.

(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors

The invention relates to the novel products of formula (I): 

1H-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of AKT (PKB) phosphorylation

The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R'1; R is selected from the group comprising Formula (A&#x2032;), (B), (C), (D), or (E), with R1 and/or R&#x2032;1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO&#x2014;NH(alkyl), CON(alkyl)2, NH&#x2014;CO-alkyl, sulfonamide, NH&#x2014;S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or &#x2014;NH&#x2014;R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs. 

HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof

Compounds of formula (I): wherein Ra, Rb, R, Xand Xare as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Growing community of inventors

Paris, France

Victor Certal